(0)

Already a DIA Member? Sign in. Not a member? Join.

Sign in

Forgot User ID? or Forgot Password?

Not a Member?

Create Account and Join

Renaissance Baltimore Harborplace Hotel

Oct 16, 2023 7:30 AM - Oct 17, 2023 6:30 PM

202 E Pratt Street, Baltimore, MD 21202, USA

Real-World Evidence Conference

Translating Insights into Real-World Value

Overview

Short Course: October 12 | Virtual

Short Course: October 13 | Virtual

Conference: October 16-17 | In-Person

In a market that is constantly adapting and adjusting to the needs of the healthcare field, real-world evidence (RWE) is becoming increasingly important for regulatory and reimbursement decision-making. Historically used for post-market safety monitoring, RWE is now integrated throughout the product development lifecycle, and has led to the real-time analysis of data to better understand and gain insights on disease, approaches to treatment, and how to substantiate coverage decisions.

DIA’s Real-World Evidence Conference will explore new, innovative applications of RWE, and deliver cutting-edge insights to leverage this knowledge to advance healthcare decision-making.


Participant Testimonials

“DIA RWE is the best RWE-related event I've attended - it has compelling speakers, strong education opportunities, and a great collective of attendees.” - Nicholaas Honig, JD, Associate Regulatory Counsel, Aetion

Need approval in order to attend? Download and fill out our Justification Letter to demonstrate to your supervisor why this is a must-attend event.


Featured

Want to learn more about Real-World Evidence Conference? You've come to the right site!

Continuing Education

Learn more

Exhibits

View our Exhibit Partners and explore our latest offerings

Learn more

Highlights & Features

Stay in the know with what's going on at the event

Learn more

Discover Baltimore!

Today’s Baltimore is a place where good ideas and ambition are the currency that matter most. It’s a place where art is seen as a catalyst for conversation, food as a means of connection, and history as an opportunity for education. It’s an essential destination full of inclusive neighborhoods where all visitors will feel invited, welcomed, and seen.
Learn More

Welcome Video!

Hear what our Chair David Martin, MD, MPH has to say about Real-world Evidence!
Learn More

Who should attend?

  • Meeting Designed For

    Join professionals from every corner of the vast realm of real-world data and real-world evidence:

    • Academia
    • Clinical Research
    • Data analytics
    • Epidemiology
    • Health Economics and Outcomes Research
    • Pharmacovigilance
    • Policy
    • Real-World Evidence
    • Real-World Data
    • Regulatory Science
    • Technology development


    • Learning Objectives

      At the conclusion of this activity, participants should be able to:

      • Identify key events related to RWE in the past 1 year period
      • Compare various data standards used for the analysis and submission of real-world data
      • Evaluate how external control arm data can be used to inform early decisions in drug development programs
      • Explain the methodological approaches underlying tokenization
      • Describe key consideration for the use of RWD and RWE to support regulatory decision-making and apply lessons learned from recent use cases (recent approvals of RWD/RWE submissions)
      • Identify how to utilize clinical notes to create a representative natural language processing (NLP) training sample
      • Explain the need for collaborative studies to address a lack of harmonization on RWD/E methodologies and quality
      • Recognize trends in clinical post-marketing commitments (PMC) and requirements (PMR) issued by US FDA in oncology and how RWE can be applied

        • Register



    Short Course or Primer

    To keep you at the forefront.

    Oct 12, 2023

    Short Course:

    How Good is Good Enough? Fit-for-Purpose Considerations for RWD/RWE for Regulatory Purposes

    Learn more

    Oct 13, 2023

    Short Course:

    Measuring the Quality of Real-World Data (RWD)

    Learn more

    Program Committee

    • David Martin, MD, MPH
      David Martin, MD, MPH Vice President, Head, PCO Center of Excellence
      Novartis, United States
    • John Concato, MD, MPH, MS
      John Concato, MD, MPH, MS Associate Director for Real-World Evidence Analytics, OMP, CDER
      FDA, United States
    • Simon Dagenais, PhD, MSc
      Simon Dagenais, PhD, MSc Real-World Evidence Lead, Internal Medicine
      Pfizer Inc, United States
    • Rachele Hendricks-Sturrup, DrSc, MA, MSc
      Rachele Hendricks-Sturrup, DrSc, MA, MSc Research Director, Real-World Evidence
      Duke-Robert J. Margolis, MD, Center for Health Policy, United States
    • Brad Jordan, PhD
      Brad Jordan, PhD Associate Vice President, Regulatory Policy and Strategy
      Eli Lilly and Company, United States
    • Nirosha M. Lederer, PhD, MS
      Nirosha M. Lederer, PhD, MS Head, US Government Partnerships; Senior Director, RWE Strategy
      Aetion, United States
    • Charles Lee, MBA, MS
      Charles Lee, MBA, MS Executive Regulatory Science Director
      AstraZeneca, United States
    • Yun Lu, PhD, MS
      Yun Lu, PhD, MS Deputy Division Director, DABRA, OBPV, CBER
      FDA, United States
    • SARAH K Martin, PhD, MS
      SARAH K Martin, PhD, MS Senior Director - Global Regulatory Policy (Oncology)
      Eli Lilly & Co., United States
    • Brittany Avin McKelvey, PhD
      Brittany Avin McKelvey, PhD Director, Regualtory Affairs
      Friends of Cancer Research, United States
    • Keri Monda, PhD, MS
      Keri Monda, PhD, MS Executive Director, Center for Observational Research
      Amgen, United States
    • Representative Invited
      Representative Invited DIA, United States

    Digital Learning Catalog

    DIA Learning: eLearning Soultions
    Download

    Have an account?

    Be informed and stay engaged.

    Don't miss an opportunity - join our mailing list to stay up to date on DIA insights and events.